title: Hypolipemiant besides antileukemic effect of imatinib mesylate.
abstract: The use of imatinib mesylate (IM) (Gleevec, Novartis) in chronic myeloid leukemia (CML) and other neoplastic disorders is in a dramatic increase, inducing long-standing survival. Therefore, the interest in the associated events with this treatment is more and more manifest. We describe a case of CML in which, at the usual antileukemic dose, IM induced a rapid and persistent normalization of the levels of serum cholesterol, triglycerides, low- and high-density lipoproteins and glucose. In the present case report we confirm other observations on the hypolipemiant and antidiabetic effects, concomitant with that antileukemic, of IM.
authors.affiliation: Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania. mds.fundeni@yahoo.com
authors.forename: Radu
authors.initials: R
authors.lastname: Gologan
authors.forename: Gabriela
authors.initials: G
authors.lastname: Constantinescu
authors.forename: Daniela
authors.initials: D
authors.lastname: Georgescu
authors.forename: Daniela
authors.initials: D
authors.lastname: Ostroveanu
authors.forename: Didona
authors.initials: D
authors.lastname: Vasilache
authors.forename: Camelia
authors.initials: C
authors.lastname: Dobrea
authors.forename: Daniela
authors.initials: D
authors.lastname: Iancu
authors.forename: Viola
authors.initials: V
authors.lastname: Popov